CN1227246C - 改进的奥美拉唑制备方法及其组合物 - Google Patents

改进的奥美拉唑制备方法及其组合物 Download PDF

Info

Publication number
CN1227246C
CN1227246C CNB998119083A CN99811908A CN1227246C CN 1227246 C CN1227246 C CN 1227246C CN B998119083 A CNB998119083 A CN B998119083A CN 99811908 A CN99811908 A CN 99811908A CN 1227246 C CN1227246 C CN 1227246C
Authority
CN
China
Prior art keywords
solution
solvent
omeprazole
methanol
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998119083A
Other languages
English (en)
Chinese (zh)
Other versions
CN1322201A (zh
Inventor
N·阿诺西斯
B·N·班克斯
J·W·麦马努斯
周令闻
刘汇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22254872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1227246(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB, Merck and Co Inc filed Critical AstraZeneca AB
Publication of CN1322201A publication Critical patent/CN1322201A/zh
Application granted granted Critical
Publication of CN1227246C publication Critical patent/CN1227246C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB998119083A 1998-08-11 1999-08-06 改进的奥美拉唑制备方法及其组合物 Expired - Fee Related CN1227246C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9603798P 1998-08-11 1998-08-11
US60/096,037 1998-08-11

Publications (2)

Publication Number Publication Date
CN1322201A CN1322201A (zh) 2001-11-14
CN1227246C true CN1227246C (zh) 2005-11-16

Family

ID=22254872

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998119083A Expired - Fee Related CN1227246C (zh) 1998-08-11 1999-08-06 改进的奥美拉唑制备方法及其组合物

Country Status (18)

Country Link
US (2) US6166213A (https=)
EP (1) EP1104417B1 (https=)
JP (1) JP2002522537A (https=)
KR (1) KR100632725B1 (https=)
CN (1) CN1227246C (https=)
AT (1) ATE360626T1 (https=)
AU (1) AU764642B2 (https=)
BR (1) BR9912883A (https=)
CA (1) CA2338967A1 (https=)
DE (1) DE69935915T2 (https=)
DK (1) DK1104417T3 (https=)
ES (1) ES2285857T3 (https=)
IL (2) IL141324A0 (https=)
NO (1) NO321054B1 (https=)
NZ (1) NZ509798A (https=)
PT (1) PT1104417E (https=)
WO (1) WO2000009497A1 (https=)
ZA (1) ZA200101140B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6303787B1 (en) * 1998-05-27 2001-10-16 Natco Pharma Limited Intermediates and an improved process for the preparation of Omeprazole employing the said intermediates
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
DE10140492A1 (de) 2001-08-17 2003-08-14 Gruenenthal Gmbh Hydrate von gegebenenfalls substituierten 2-(2-Pyridinyl)methylthio-1H-benzimidazolen und Verfahren zu ihrer Herstellung
WO2003063840A2 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
KR100873419B1 (ko) * 2002-06-18 2008-12-11 페어차일드코리아반도체 주식회사 높은 항복 전압, 낮은 온 저항 및 작은 스위칭 손실을갖는 전력용 반도체 소자
EP1764364A1 (en) * 2002-08-21 2007-03-21 Teva Pharmaceutical Industries Ltd A method for the purification of lansoprazole
US6909004B2 (en) * 2002-08-21 2005-06-21 Teva Pharmaceutical Industries Ltd. Method for the purification of lansoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
PL1802584T3 (pl) * 2004-10-11 2010-03-31 Ranbaxy Laboratories Ltd Sposób wytwarzania podstawionych sulfotlenków
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
WO2007066202A1 (en) * 2005-12-06 2007-06-14 Inogent Laboratories Private Limited Process for the preparation of 2-(2-pyridylmethyl)-sulfinyl-1h-benzimidazoles
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
CA2667682A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
CN103204841B (zh) * 2013-05-09 2014-06-25 成都天台山制药有限公司 奥美拉唑钠及制备方法
CN104592201A (zh) * 2015-01-13 2015-05-06 江苏中邦制药有限公司 一种奥美拉唑的精制方法
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN111635393A (zh) * 2020-06-28 2020-09-08 江苏吴中医药集团有限公司 一种艾司奥美拉唑钠的制备方法
CN112679475B (zh) * 2021-01-14 2022-02-15 四川新迪医药化工有限公司 一种奥美拉唑的制备方法及奥美拉唑
WO2023048508A1 (ko) * 2021-09-23 2023-03-30 국립암센터 오메프라졸 갈변물질을 포함하는 암 예방 또는 치료용 약학적 조성물
CN114209697A (zh) * 2021-12-14 2022-03-22 重庆大学附属三峡医院 一种质子泵抑制剂、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPH0643426B2 (ja) * 1986-07-25 1994-06-08 東京田辺製薬株式会社 イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
GB2239453A (en) * 1989-11-27 1991-07-03 Haessle Ab Omeprazole
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
ES2026761A6 (es) * 1990-10-31 1992-05-01 Genesis Para La Investigacion Procedimiento de obtencion del omeprazol.
WO1993006097A1 (en) * 1991-09-20 1993-04-01 Merck & Co., Inc. Novel process for the preparation of anti-ulcer agents
TW359614B (en) * 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
AU5780696A (en) * 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
SE521100C2 (sv) * 1995-12-15 2003-09-30 Astra Ab Förfarande för framställning av en bensimidazolförening
SK283805B6 (sk) * 1996-09-09 2004-02-03 Slovakofarma, A. S. Spôsob prípravy omeprazolu
WO1998040378A1 (en) * 1997-03-07 1998-09-17 A/S Gea Farmaceutisk Fabrik Process for the preparation of 2-[[(2-pyridinyl)methyl]sulfinyl]-1h-benzimidazoles and novel compounds of use for such purpose
WO1998040377A1 (en) * 1997-03-07 1998-09-17 A/S Gea Farmaceutisk Fabrik Process for the preparation of 2-[[(2-pyridinyl)methyl]sulfinyl]-1h-benzimidazoles and novel compounds of use for such purpose

Also Published As

Publication number Publication date
IL141324A0 (en) 2002-03-10
KR100632725B1 (ko) 2006-10-16
EP1104417B1 (en) 2007-04-25
PT1104417E (pt) 2007-06-29
WO2000009497A1 (en) 2000-02-24
CA2338967A1 (en) 2000-02-24
DK1104417T3 (da) 2007-07-16
DE69935915T2 (de) 2008-01-10
CN1322201A (zh) 2001-11-14
EP1104417A1 (en) 2001-06-06
NO20010677D0 (no) 2001-02-09
ATE360626T1 (de) 2007-05-15
KR20010072382A (ko) 2001-07-31
EP1104417A4 (en) 2002-12-18
DE69935915D1 (de) 2007-06-06
BR9912883A (pt) 2001-09-25
US6147103A (en) 2000-11-14
IL141324A (en) 2007-05-15
AU764642B2 (en) 2003-08-28
US6166213A (en) 2000-12-26
NZ509798A (en) 2003-06-30
JP2002522537A (ja) 2002-07-23
NO20010677L (no) 2001-04-09
NO321054B1 (no) 2006-03-06
ES2285857T3 (es) 2007-11-16
ZA200101140B (en) 2002-04-09
AU5470999A (en) 2000-03-06

Similar Documents

Publication Publication Date Title
CN1227246C (zh) 改进的奥美拉唑制备方法及其组合物
CN1161351C (zh) 新型s-奥美拉唑
EP2308492B1 (en) Process for preparing lansoprazole
EP2842953A1 (en) Process for the preparation of esomeprazole magnesium dihydrate
US6191148B1 (en) Omerazole process and compositions thereof
EP2195309A2 (en) Polymorphs of esomeprazole salts
RU2197486C2 (ru) Усовершенствованный способ синтеза 5-метокси-2-[(4-метокси-3,5-диметил-2-пиридил)метил]сульфинил-1н-бензимидазола
JP5355893B2 (ja) パントプラゾールナトリウムの製造方法
US8907100B2 (en) Lansoprazole compound and novel preparation method thereof
CN108440502B (zh) 一种制备奥美拉唑钠有关物质的方法
CN106279108B (zh) 一种工业化生产雷贝拉唑及右旋雷贝拉唑中间体的方法
HK1034510B (en) Improved omeprazole process and compositions thereof
HK1034510A1 (en) Improved omeprazole process and compositions thereof
WO2010004571A2 (en) Process for purification of rabeprazole sodium
CN118271289A (zh) 一种艾司奥美拉唑钠的制备方法
MXPA01001542A (en) Improved omeprazole process and compositions thereof
EP1975169A1 (en) Process for the preparation of ziprasidone
CN110256354A (zh) 一种二丙酸咪唑苯脲杂质a及其杂质a制备方法
EP1818331A1 (en) Process for the preparation of 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole substantially free of sulfone impurity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ASTRAZENCA AB

Free format text: FORMER OWNER: MERCK + CO., INC.

Effective date: 20021114

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20021114

Address after: Swedish Sodertalje

Applicant after: Astra Zeneca Aktiebolag

Address before: New Jersey, USA

Applicant before: MERCK & Co.,Inc.

C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee